151 related articles for article (PubMed ID: 35432159)
1. Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis.
Zheng Y; Yuan X; Zhang C; Liu R; Jin H; Hao H; Li F; Zhao Y; Yuan Y; Wang Z; Gao F
Front Neurol; 2022; 13():843523. PubMed ID: 35432159
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
4. Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis.
Peng Y; Jiang F; Zhou R; Jin W; Li Y; Duan W; Xu L; Yang H
Neuropsychiatr Dis Treat; 2021; 17():2281-2289. PubMed ID: 34285488
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study on Tocilizumab in Very-Late-Onset Myasthenia Gravis.
Yang TT; Wang ZY; Fan ZX; Yuan BY; Ma L; Lu JF; Liu PJ; He Y; Liu GZ
J Inflamm Res; 2023; 16():5835-5843. PubMed ID: 38088944
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
8. Late-onset myasthenia gravis is predisposed to become generalized in the elderly.
Sakai W; Matsui N; Ishida M; Furukawa T; Miyazaki Y; Fujita K; Miyamoto R; Yamamoto N; Sako W; Sato K; Kondo K; Nishida Y; Mitsui T; Izumi Y; Kaji R
eNeurologicalSci; 2016 Mar; 2():17-20. PubMed ID: 29473057
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
12. Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients.
Fan Z; Li Z; Shen F; Zhang X; Lei L; Su S; Lu Y; Di L; Wang M; Xu M; Da Y
Front Neurol; 2020; 11():594152. PubMed ID: 33193063
[No Abstract] [Full Text] [Related]
13. The emerging role of tacrolimus in myasthenia gravis.
Cruz JL; Wolff ML; Vanderman AJ; Brown JN
Ther Adv Neurol Disord; 2015 Mar; 8(2):92-103. PubMed ID: 25922621
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between clinical manifestation, prognosis and antibody in anti-muscle-specific tyrosine kinase antibody positive myasthenia gravis].
Tan Y; Zhu L; Huang YY; Shi JY; Li J; Li K; Guan YZ; Cui LY
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2433-2437. PubMed ID: 34399555
[No Abstract] [Full Text] [Related]
15. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
16. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis.
Vijayan J; Menon D; Barnett C; Katzberg H; Lovblom LE; Bril V
Muscle Nerve; 2021 Oct; 64(4):462-466. PubMed ID: 34235762
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
19. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis.
Fan Z; Lei L; Su S; Zhang S; Xie N; Li L; Lu Y; Di L; Wang M; Xu M; Shen XM; Da Y
Ann Clin Transl Neurol; 2023 Apr; 10(4):589-598. PubMed ID: 36808840
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.
Meng X; Zeng Z; Wang Y; Guo S; Wang C; Wang B; Guo S
Neuropsychiatr Dis Treat; 2022; 18():953-964. PubMed ID: 35535211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
